Acute Porphyria Drug Database

Monograph

C10AB05 - Fenofibrate
Propably not porphyrinogenic
PNP

Rationale
Substrate of CYP 3A4. No data pointing to CYP-inducing properties.
Chemical description
Prodrug to the lipid lowering agent phenofibrate acid. Dose 200 mg/d. Metabolized by CYP 3A4. No indications of CYP-induction.
IPNet drug reports
Uneventful use reported in 5 patients with acute porphyria.
Similar drugs
Explore alternative drugs in similar therapeutic classes C10A / C10AB or go back.
Tradenames
This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.


Fenogal Fenofibraat · Fenofibrate · Fenogal Lidose · Fenosup Lidose · Lipanthyl Fenofibrato · Secalip · Secalip Supra Fenofibrato · Fulcro · Fulcrosupra · Liperial · Lipofene · Lipsin Fenofibrat · Lipanthyl · Lipantil · Lipivim · Lipofib Fenofibrate · Fenofibrate micronised · Fenogal · Lipantil · Supralip Fenofibrat · Fenolip · Lipanthyl · Lipantil · Lipofene · Thylip Apo-Feno · Biofibrat · Fenardin · Fibralipid · Grofibrat · Grofibrat M · Grofibrat S · Lipanthyl Fegenor · Fenofibrate · Fenogal Lidose · Lipanthyl Lipanthyl Lipanthyl Fenolip · Lipanthyl · Zyglip
 
© NAPOS 2025
An unhandled error has occurred. Reload 🗙